The enzymes which transcribe DNA synthesizing RNA (DNA-dependent RNA polymerases) have structural differences in eukaryotic and prokaryotic cells, as indicated by the fact, among others, that there are substances which inhibit their function selcctivcly in prokaryotic cells (streptolydigin and the ansa antibiotics, such as rifamycins and streptovaricin) and in eukaryotic cells (Cl-amanitin). Ansa antibiotics inhibit the initiation of RNA synthesis, whereas streptolydigin interferes with RNA elongation. Among ansa antibiotics, rifamycins have been studied more extensively, in order to obtain semisynthetic derivatives which, besides a comparable in vitro activity, showed better pharmacokinetic properties in vivo. Rifampicin, 3-(4-methylpiperazinoiminomethyl) rifamycin SV, has been selected for the oral treatment ofvarious bacterial infections. Furthermore, a series of correlations between structure and activity have been derived, leading to the recognition of the essential structural requirements, of the rifamycin molecule for penetrating into the bacterial cell and foi-inhibiting the enzyme.
INTRODUCTION
Chemotherapeutic agents used in the treatment of infectious diseases possess, as a necessary but not sufficient requisite, a selective toxicity against pathogens. Therefore, they must act on specific targets which are present in the parasite but are either absent in the host or sufficiently different to be discriminable in the two organisms. In some cases, selective toxicity depends on the fact that the chemotherapeutic agent can reach the specific target in the microorganism but not in the host cell because of a selective permeability.
The search for chemotherapeutic agents has generally proceeded in an empirical way, namely, by means of a massive screening of products obtained by chemical synthesis or from natural sources, such as antibiotics, and through comparative tests of toxicity on the microorganism and host. So far this empirical approach has produced a series of useful chemotherapeutic agents that nowadays permit a successful control of most infectious diseases. Notwithstanding such successes, the necessity persists of carrying on the search for new chemotherapeutic agents with higher selectivity of action, P. SENST lower side-effects and an unchanged efficacy on the microorganisms resistant to current chemotherapeutic agents.
Probably Jwwever, the search for new chemotherapeutic agents has reached a critical point. In fact, the nurober of new efficacious drugs produced in the last few years is very small although a systematic and massive effort has been maintained in the search for new synthetic compounds or microbial metabolites with antibacterial properties. On the other hand, the knowledge of cell structure and of comparative biochemistry has increased considerably. 1t has become clear that, besides the underlying unity ofbiochemical processes which occur in all forms of life, there are some differences in the biochemical pathways of diverse species. A knowledge of the structural or biochemical differences between prokaryotes and eukaryotes permits the selection of specific targets for new chemotherapeutic agents. lt must be acknowledged frankly that, till now, such targets have been identified a posteriori. The discovery of chemotherapeutic agents has always preceded the explanation oftheir mechanism of action and, therefore, the characterization ofthe specific target on which they are directed. However, the interval of time elapsing between the discovery of a chemotherapeutic agent and the understanding of its mechanism of action is very short nowadays, tending to become an unitary process.
Presumably, the knowledge of biochemical processes in the various species may constitute, in the future, the basisforarational development of new chemotherapeutic agents. It is clear that such a development does not only mean the ambitious possibility of designing a priori molecules suitable for hitting a particular target, that is the dream, too often not fulfilled, of each medicinal ehernist But the knowledge of particular targets allows the setting up of definite biological laboratory tests, fit for selecting products with a given mechanism of action. At thc same time, this knowlcdge allows an orientation of the chemical or biochemical synthesis towards classes of products which, at least theoretically, could interfere with the chosen target.
A nurober ofenzymatic systems having the same role but different structures in various species, have been discovered so far. They can be chosen as specific targets useful in the search for new chemotherapeutic agents. As a classical example, I would cite the dihydrofolate reductase enzyme. This enzyme catalyzes the synthesis of tetrahydrofolic acid, a cofactor of the C 1 -transferase enzyme, which participates in the synthesis of purines and certain amino acids both in prokaryotes and eukaryotes. Dihydrofolate reductase is inhibited by a nurober of2,4-diaminopyrimidines. The synthesis and testing ofa large nurober of2,4-diaminopyrimidines and related substances, revealed that considerable selectivity could beachieved through molecular modification of the inhibitor. Some substances in this group have found clinical applications. Table 1 shows the selective action of pyrimethamine and trimethoprim against dihydrofolate reductase from different sources, and explains their use respectively as antimalarialand antibacterial agents 1 . Another dass ofspecifictargets is constituted by the transcriptases, enzymes which synthesize RNA using DNA as a template (DNA-dependent RNA polymerases). Theseenzymes have a analogous role, but a different structure in prokaryotes and eukaryotes. This is shown by the fact that there ar~ substances that selectively block their function either in eukaryotes {ct- 
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berghei erythrocyte liver Table 2 shows the selective activity of these inhibitors. The discovery of such inhibitors has preceded the understanding of their mechanism of action, but the subsequent knowledge of this mechanism has catalyzed the search for analogaus structures, obtainable, for instance, through chemical modifications ofnatural products, in order to obtain inhibitors oftranscriptases in species others than sensitive bacteria. The results of this search, together with its prospects, are just the subjects of this report.
TRANSCRIPfASE (DNA-DEPENDENT RNA POLYMERASE): STRUCTURE AND FUNCTION
Transcriptase is the enzyme which catalyzes the polymerization of four ribonucleoside triphosphates into RNA, by transcribing a DNA template. In this way, the genetic information is transferred to RNA from DNA, with a sequence that is complementary tothat of DNA template.
Eukaryotic transcriptase
The structure and the functioning of eukaryotic transcriptase is not weil understood. At least three DNA-dependent RNA polymerases have been distinguished in eukaryotes. Polymerase I resides in the nucleolus and polymerase Il and III in the nucleoplasm. They can be separated by chromatography on a DEAE-Sephadex column. Their reciprocal ratios seem to be different among the various species, and in the subsequent stages of development in the same species. Polymerase I synthesizesmainly, but not exclusively, ribosomal RNA; polymerase li synthesizes the bulk of nucleoplasmic RNA species, and polymerase III has no defined role as yet 2 • Recent sturlies on the structure of polymerase II from calf thymus and rat liver indicate that the molecule contains four components with ~olecular weight respectively of 190 000, 150 000, 35 000 and 25 000. Another species of polymerase II, with the largest component having a molecular weight of 170 000, has been identified in the same preparations. One of these forms may be derived from the other 3 .
Prokaryotic transcriptase
This enzyme has been studied in several organisms. Most information has been obtained with the RNA polymerasefromEscherichiacoli. However, there are good grounds for believing that the structure and properties of this enzyme are very similar in the various kinds of bacteria. The RNA polymerase of E. coli is constituted of several subunits: two rx, ß,ß' and cr (see Table 3) 4 . All together, they constitute the holoenzyme, and the first four subunits constitute the core enzyme.
INHIBITORS OF THE TRANSCRIBING ENZYMES
The enzymatic reaction occurs through the following steps: (i) Binding. The enzyme (Enz) binds the template (DNA):
At the initiation site, the DNA-Enz complex binds a purine nucleoside triphosphate which will constitute the 5' -terminal of the RNA chain, with the formation of a ternary complex:
A second nucleoside triphosphate (PPPX, X = purine ör pyrimidine nucleoside) is then bound with the formation ofthe first phosphodiester bond and elimination of pyrophosphate (PPy):
The enzyme migrates on DNA, while the nucleoside monophosphates PX, complementary to those of the DNA template, are added to the 3' end of the growing RNA chain:
DNA-Enz-PPPPur-PX + n 1 PPPX ~ DNA-Enz-PPPPur-{PX)n + n 1 PPy (iv) Termination. When the transcribing machinery reaches the end of a cistron or of a polycistronic message, the polymerization process stops and the DNA-Enz-RNA complex dissociates:
The processes of initiation and termination are more complex than indicated in the above simplified scheme, because they require other factors regulating them. The cr unit has a role in the recognition and initiation of transcription of certain genes on DNA, but the process of chain elongation is determined by the core enzyme. The structural and functional differences between RN A polymerase of prokaryotes and eukaryotes may constitute the basis for a rational development of chemotherapeutic drugs, acting on this specific target. Figure 1 . cx-Amanitin. bacterial RNA polymerase. As an illustration of the degree of specificity, it can be cited that nucleolar RNA polymerase II from rat liver is inhibited to the extent of50 per cent at 10-8 M and to the extent oflOO per cent at 10-6 M of cx-amanitin, while at the same concentrations, neither polymerase I and III of eukaryotes nor prokaryotic polymerase are inhibited to any significant extent
The enzymatic reaction is blocked immediately after adding the inhibitor, which seems to act at the stage of RNA-chain elongationo The eukaryotic RNA polymerase from yeast is much less sensitive to the action of cx-amanitin than the mammalian enzyme 8 0 cx-Amanitincanconstitutearemarkableexampleofthepossibilityoffinding substances with a selectivity of action on enzymes that, although having a similar role, have a different structure in the various species. Furthermore, its polypeptidic nature could constitute a suitable model for the synthesis and testing of analogaus polypeptidic compounds, in order to obtain information concerning the part ofthe molecule of cx-amanitin responsible for the binding to RNA polymerase II of eukaryotesolt is possible that, by introducing suitable groups such as aminoacidic residues, the molecule may acquire the property of binding to other polymerases.
Specific inhibitors of prokaryotic transcriptase
Streptolydigin. Streptolydigin is an antibiotic produced by Streptomyces lydicus 9 . Its structure is shown in Figure 2 . It exhibits in vitro activity primarily against streptococci, diplococci and clostridia and is relatively nontoxic. lt acts by binding and thus specifically inhibiting bacterial RNA polymerase. In contrast, it has no effect on polymerase from calfthymus 10 . lts binding to
the bacterial enzyme seems to be rather weak, since the inhibition is reversed by dilution. The concentration of antibiotic required for complete inhibition is fairly high (about 10-4 M), although a 50 per cent inhibition is obtained at about 7 x 10-6 M. Streptolydigin interferes with the process of RNA chain elongation, primarily by affecting the rate ofphosphodiester bond formation 1 
~
Only at high concentrations of the drug is the initiation process affected, because the formation of the first phosphodiester bond is also inhibited.
Chemical modifications of streptolydigin have not been performed, so it is not possible to elucidate which groups ofthe molecule are responsible for the binding to the enzyme.
Streptolydigin has no clinical application, although it shows the requisite of a selective activity on prokaryotes. lt is opportune to recall again the fact that the selectivity of action is an essential, but not sufficient requisite for a chemotherapeutic agent.
Rifamycins, tolypomycins and streptovaricins. Rifamycins, together with tolypomycins and streptovaricins, arenatural ansa compounds in which an aliphatic bridge spans an aromatic system. vatives have been obtained through chemical modifications of rifamycin B, with the aim of obtaining products for therapeutic applications in the field of bacterial infect'ions. These extensive sturlies have not only yielded three semisynthetic rifamycins now in clinical use (namely, rifamycin SV, rifamide and rifampicin) ( Figure 6 ), but have led to the recognition of the main structural requirements for penetration into bacterial cell and for inhibition of the enzyme.
--~--------t The numbering system followed in this text for the rifamycins is that originally used by
Prelog et a/. 1 Figure 4 . Numbering: system for rifamycin B according, to IUPAC rules. system has been used so far in allliterature on the rifamycins and related 'ansamycins'. Tbc orientation and numbering system for the rifamycins, according to the IUPAC rules, is shown in Tolypomycin (Figure 7) is an. antibiotic substance produced by S. tolypophorus25· 26 . From its structure it can be considered a member of the rifamycin family, the main difference being the presence of the aminosugar, tolyposamine, in position 4. The product of mild acid hydrolysis, tolypomycinon, corresponds to rifamycin S with a methyl group and the adjacent double bond replaced by the cyclopropane ring and the carbonyl group, respectively. Streptovaricin, produced by S. mirabilis 27 , is a complex mixture of several related compounds whose structures are indicated in Figure 8 
•
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Rifamycins, tolypomycins and streptovaricins are very active against Gram-positive bacteria and mycobacteria. Some members of this large group of natural and semi-synthetic antibiotics showalso moderate activity against Gram-negative bacteria. Microorganisms resistant to one dass of these antibiotics are also resistant to the others.
The mechanism of action on bacteria is identical for rifamycins, streptovaricins and tolypomycins. It will be referred to in detail here for the rifamycins, and in particular for rifampicin, which have been studied more extensively.
Rifamycins selectively inhibit the synthesis of all cellular RNA in sensitive bacteria 30 393 50 per cent decrease of the bacterial enzymatic activity. In intact bacteria the inhibition by rifamycins ofprotein synthesis and ofDNA synthesis is a consequence of the primary effect of these antibiotics on RNA synthesis 33 · 34 .
The mammalian RNA polymerase is resistant to even very high concentra-, tions of rifamycins 31 ( Figure 9) .
The high ratio of activity of rifamycins against bacterial and mammalian RNA polymerase could not be utilized for chemotherapeutic applications if these antibiotics inhibited the RNA polymerase ofmitochondria of eukaryotic organisms, which have some biochemical properties similar to those of prokaryotes. Results of studies on the activity of rifamycins on mitochondrial RNA polymerase are conflicting. Some reports indicate that rifampicin does not inhibit the RNA synthesis by mitochondria from yeast 35 · 36 , N eurospora 31 and hamster cells 38 , whereas those cases where rifampicin has been reported to affect mitochondrial-RNA synthesis, i.e. in rat liver or bovine heart 39 - 41 , very high concentrations of antibiotics were needed for the inhibition. 10 100 In bacteria rifamycins inhibit the initiation of RNA synthesis and have no effect on chain elongation 31 ' 42 . They do not inhibit the formation of the enzyme-DNA complex, so their activity is probably due to their ability to ~odify the confor~ation of th~ enzyme, inactivati!lg it before the incorporahon of the first punne nucleohde of the RNA cham. As previous incubation o~ the holoe~zyme ~ith the ?at_u~al DNA templ~te in presence of Mg2+ giVes protechon agamst the mhtbttory effect of nfamycins, it seems likely that these antibiotics inhibit the transformation of the DNA-enzyme 394 complex into an activated form, during which the enzyme binds to the specific promoter sites on the DNA 43 -45 . Rifamycins inhibit the RNA polymerase forming a rather stable complex with it 46 -48 • The binding between enzyme and rifamycins with the formation of an equimolecular complex is a very quick process 46 . The complex is rather stable but no covalent linkages are involved because it slowly exchanges with free rifamycin 48 , and is dissociated with 6M guanidine hydrochloride 43 . Rifamycins also bind to the enzyme during the RNA chain elongation, but have no effect on this process, perhaps because the enzyme, at this stage, is resistant to conformational changes induced by the antibiotic.
Bacterial mutants resistant to rifamycins possess an altered RNA polymerase which is not inhibited by rifamycins 49 • 50 . Studies on the interaction between rifamycins and the various subunits of the enzyme have shown that rifamycin binds to the ß-subunit 51 . This has been confirmed by the finding that. in rifampicin-resistant mutants, RNA polymerase contains a subunit with an electrophoretic mobility different from that ofwild-type ß, likely as a consequence of the su bstitution of a single charged amino acid 52 · 53 .
STRUCTURAL MODIFICATIONS OF THE RIFAMYCINS AND THEIR EFFECT ON ANTffiACTERIAL ACTIVITY
Changes affecting penetration of rifamycins into the bacterial cell With few exceptions, most rifamycins are active against bacteria when they are active against the bacterial RNA polymerase and vice-versa (Table 4 ). The exceptions, indicated as dass 3 in the Table, are constituted by rifamycms bearing a strong polar group (e.g. a free carboxy group), which are active against the enzyme but have little or no activity against intact bacterial cells, because a permeability barrier exists, which the polar derivatives cannot pass 47 • 54 . Such derivatives would be discarded, as inactive or little active, in a blind conventional screening for the search for antibacterial agents. On the contrary, a screening directed against the target enzyme, the bacterial RNA polymerase, would select such derivatives, leaving to the medicinal ehernist the possibility of modifying their structure in order to increase their permeability through the cell wall. Also rifamycin B belongs to this group; but although inactive per se, it is easily transformed into rifamycin S, which is very active, and only as a result of this unusual property has not been neglected 55 . Although large variationsexist in the sensitivity of different intact bacteria to a particular rifamycin, no such differences are apparent when the isolated transcriptase is examined. Thus in the case of the Gram-negative bacteria permeability plays an overriding role in determining the sensitivity to rifamycins; their enzyme has an intrinsic sensitivity very similar to that of the Gram-positive bacteria.
A few rifamycins show activity on the intact cells and no activity on the RNA polymerase and this is due to the fact that they undergo some chemical modification during the antibacterial test. For example 8-acyl rifamycins are inactive against the enzyme 54 , but kill the bacteria because they undergo deacetylation during the incubation.
Structure-activity relationship for inhibition of transcriptase from sensitive bacteria
By making use ofthelarge range of semi-synthetic rifamycins available, it has been possible to investigate the essential structural requirements of the rifamycin molecule for inhibition of the bacterial RNA polymerase. So far results have shown that changes of the ansa chain involving substitution or elimination of the two hydroxy groups at C-21 and C-23 yield inactive products, while the acetoxy group at C-25 and the methoxy group at C-27 seem to be unessential requirements. For example, methanolysis of rifamycin S in mildly acidic conditions, yields the 23, 27 -epoxy derivative which no Ionger has the hydroxy group at C-23 and is inactive 47 • 59 . Also the 21-and 23-0-acetyl rifamycins S have a very poor activity 58 . On the other band, the acetoxy group at C-25 can be hydrolyzed without loss of activity 59 . Among natural rifamycins, the 27-0-demethyl rifamycin S shows a high Ievel of activity, while rifamycin Y, with a keto group instead of an hydroxy group at C-21, is practically inactive 11~. It is interesting to pointout that tolypomycin Y and streptovaricin A, C and D, which are very active, all have the hydroxy groups in positions corresponding to the 21 and 23 of the rifamycins.
Functional modifications which, although leaving the hydroxy groups at C-21 and C-23 unaltered, produce important changes in the conformation of the ansa chain, also give inactive or only moderately active products. Thus hexahydro rifamycin S shows very little antibacterial activity, while the dihydro and the tetrahydro analogues are quite active 56 • 59 . The monoand di-epoxides ofrifamycin S, obtained by treatment with monoperphthalic acid, show a poor activity and the iminomethylether, obtained by treatment with CH 3 1, has a negligible activity 56 ' 59 (see Figure 1 0) . In all these cases, the molecular models and certain physicochemical characteristics indicate that such chemical changes have caused a modification in the conformation of the ansa chain.
The hydroxy group attached at C-8 ofthe chromophoric moiety also seems to be an essential structural requirement, since 8-methoxy rifamycin S is inactive 60 • On the contrary, the hydroxy groups on the positions C-1 and C-4 can be substituted by keto groups without loss of activity. The same quinone~ hydroquinone system does not appear essential, since 4-<leoxyrifamycin is also quite active, although its activity is approximately one-tenth that of rifamycin SV 56 (see Figure 12 ). Thus, from the data accumulated until now, it can be inferred that the essential structural requirements for the inhibition of the bacterial RNA polymerase, are free hydroxy groups at C-21, C-23 and C-8, tagether with a certain conformation of the ansa chain, leading to adefinite geometric relationship between these groups, as can be seen in the three-dimensional model (Figure 11 ). Some di_fferences have been obs~rve? in the in. vitro antibacterial activity of the vanous classes of these denvahves, but they are most likely due to differences in the ability to penetrate into the bacterial cell, rather than to differences in the activity on RNA polymerase. As an example, Table 5 398 TH3 CHI P. SENST reports the activity of rifampicin and rifamycin AG against several bacteria and against RNA polymerase. Although rifamycin AG is about 20 times more active than rifampicin against E. coli, the RNA polymerase extracted from this bacterial species is equally sensitive to both substances 60 . These chemical modifications on the aromatic moiety have produced dramatic changes on the pharmacokinetic behaviour of the resulting rifamycins in comparison with rifamycin SV, the first rifamycin used in therapy for the treatment ofseveral infectious discases. This modified pharmacokinetic behaviour is, in turn, the result of changes in physicochemical parameters (such as solubility and partition coefficient in water and Iipids).
INHIRITORS OF THE TRANSCRIBING ENZYMES
Rifampicin 69 • 71 has been selected out of several hundred derivatives for its high in vivo activity per os and is now successfully used for the oral treatment of Gram-positive and some Gram-negative infections and tuberculosis 72 . The field of rifamycins is another example showing that the selectivity of action against bacteria is a necessary requisite for the development of a potential chemotherapeutic agent, but that its practical usefulness depends on several other factors (absorption, distribution, rate of eliminabon, metabolism, interaction with proteins, etc.).
Modifications resulting in activity against rifampicin-resistant bacterial mutants
A possible target for new chemically modified rifamycins is the RNA polymerase of resistant bacteria, with the aim of overcoming the possible decline in the therapeutic value of these antibiotics as a consequence of the Table 6 . Activity of some rifamycin derivatives against sensitive and resistant strains of S. aureus OH ,. ~~ ~~ ., '*'
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emergence of organisms insensitive to them. As mentioned, in the resistant mutants the subunit ß of the RNA polymerase is modified and is no more affected by rifampicin and by the other rifamycins in clinical use. Testing hundreds of semisynthetic rifamycins, it has been found that some groups of derivatives inhibit, at concentration inferior to 20 J..Lg ml-1 , the growth of a Staphylococcus strain resistant to more than 200 J..Lg ml-1 of rifampicin. In Table 6 two groups of derivatives are reported: the oximes of the 3-formylrifamycin SV 7 \ and the 3-N,N -disubstituted aminorifamycins 74 .
Although the oximes do have a certain activity on the isolated RNA polymerase from rifampicin-resistant bacteria, it cannot be concluded that this is the only responsible mechanism of inhibition of the intact bacteria. The oximes inhibit other enzymes as weil (see reverse transcriptase p. 407) and have lost, at least partially, the specificity of the parent molecule.
The 3-N,N-disubstituted aminorifamycins active on S. aureus resistant to rifampicin had no effect on the RNA polymerase extracted from the resistant cells. In this case a different mechanism of action should be responsible for this activity on resistant mutants. The compounds reported in Table 6 have no practical interest, because their minimal inhibitory concentration is too high to foresee a therapeutic use for them, but the case of oximes is indicative that some structural modifications of the rifamycin molecule could permit the obtaining of inhibitors of the RNA polymerase resistant to rifampicin.
ACTIVITY OF RIFAMYCINS ON VIRAL TRANSCRIPT ASES
Transcriptase from mammalian cytoplasmic DNA viruses A DNA-dependent RNA polymerase is contained in the virions of some large mammalian cytoplasmic DNA viruses such as pox viruses 7 5 . Specific inhibitors of this enzyme might be potentially useful antiviral agents. Rifampicin was found to inhibit the growth of pox viruses, but its viral inhibitory dose ( 100 J..Lg ml-1 ) is from 1 000 to 10 000 tim es high er than the anti bacterial one 76 • 77 . The mechanism of the antiviral activity of rifampicin has been the object of many studies with conflicting conclusions. Although the antibiotic shows some action on the transcription of the viral genome, the inhibition ofvaccinia virus growth seems tobe related to a block in the assembly of preformed structural polypeptides of the virion 7 s-so. Other evidence that the mechanism of action of rifampicin against pox viruses is different from that against bacteria derives from the fact that virion-associated RNA polymerase of resistant mutants is sensitive to the same concentrations of rifampicin as the wild-type 81 • Furthermore, a number of different rifamycin derivatives active on the bacterial polymerase arenot inhibitory of vaccinia plaque formation 8 t. 82 . On the other hand, it has been reported that one rifamycin derivative; 23-dehydroxy-27-demethoxy-23,27 epoxyrifamycin SV (see Figure 1 0 ), which does not react with the bacterial polymerase, inhibits the vaccinia virus enzyme 83 . This fact indicates that some structural changes on the ansa chain could confer on the rifamycin molecule the property of blocking the viral enzyme. Assuming that the mechanism of action of rifampicin is different in bacteria and viruses, the discovery of its antiviral activity can be considered as a case of serendipity. 403
Until now neither rifampicin nor other semisynthetic rifamycins show significant therapeutic activity in experimental viral infections.
Reverse transcriptase (RNA-dependent DNA polymerase) from oncogenic RNA viruses
It i~ known that tumours can be induced in animals by various chemical, pbysical and biological triggers. Many DNA and RNA viruses are oncogenic in animals. They do not multiply in the cell causing its death, but determine a morphological transformation of the cell, whose subsequent multiplication is in part controlled by viral genes, integrated into the cell genome. In the case of DNA tumour viruses, replication of the viral genetic material and its expression is basically in symbiosis with the host metabolism. Also for the RNA oncogenic viruses, which constitute a large group of animal viruses, also called leukoviruses, the viral information is integrated into the cell genome and is transmitted to the daughter cells.
The structure containing the viral information was called provirus by RNA-dependent DNA polymerase activity has been found in the milk of women from families with a history of breast cancer. Such milk was also found to contain particles morphologically identical to the type B mouse mammary tumour virus 87 . A similar enzymatic activity has been identified in leukocytes of some patients with acute leukaemia and not in lymphocytes of healthy subjects even when mitosis was induced with phytohaemagglutinin88· 89 . The molecular weight ofthe enzymes from avian myeloblastosis virus and from Rous sarcoma virus have been reported to be about 110 000 and that from Rauscher leukaemia virus about 70 000
90 --92 • The structure of the enzyme(s) is not known. · The RNA-dependent DNA polymerase activity is sensitive to ribonuclease and requires all four deoxyribonucleotides for the reaction. The activity is stimulated by the addition of exogenous, synthetic DNA-RNA hybrid templates.
The reverse transcriptase ofRNA tumour viruses ofhuman acute leukaemic cells can be distinguished from known normal cellular DNA-directed DNA polymerases on the basis of its response to certain oligomer-homopolymer complexes 93 • 94 . In fact, reverse transcriptase responds very weil to oligo(dT). poly(rA) templates and very poorly to oligo(dT).poly(dA) templates, while DNA polymerases' of calf thymus or normal human lymphocytes and of bacteria have a different behaviour. The ratio of DNA polymerase activity using the two indicated oligopolymer-homopolymer complexes as templates is indicative of the reverse transcripfase activity.
Although the aetiology of human neoplasia is not known, a number of hypotheses implicate the reverse transcriptase at some stage in the process of cancerogenesis.
Inhibitors of the reverse transcriptase could constitute a powerful tool for understanding the role of reverse transcriptase in viral cancerogenesis, and perhaps could have an inhibitory effect on tumour induction or on tumour growth. Rifamycins and streptovaricins have been tested for their effect on reverse transcri ptase.
Rifampicin was found tobe inactive, but some derivatives with modified aminopiperazine side chains showed an inhibitory effect on reverse transcriptase ofMSV (murine sarcoma virus) Fe LV (feline leukaemia virus) and AMV (avian myeloblastosis virus). The most active ones were initially indicated to be rifamycins AF I ABD P (2,6-dimethyl-4-benzyl-4-demethyl-rifam picin), AF/ ABP (4-benzyl-4-demethyl-rifampicin) and AF/ AP (4-demethyl-rifampicin)95·
96 . The three rifamycins inhibited the enzyme activity more than 50 per cent at 50 to 100 jlg ml-1 . The most effective inhibitor, AF IABDP, blocked 95 per cent to 100 per cent of the enzyme activity at 100 jlg ml- The streptovaricin complex has been reported to cause a 75 per cent inhibition of the reverse transcriptase activity of ML V (Moloney leukaemia virus) at a concentration of 40 jlg ml- 1 97 . Other in vitro effects of ansamycins on the oncogenic RNA viruses have been observed. Rifampicin inhibits focus formation in chick embryo cells infected by Rous sarcoma virus 98 and rifamycin AF I ABDP inhibits transformation of mouse cells by murine sarcoma virus 99 . All these data stimulated a search for potent inhibitors of the reverse transcriptase and more than 200 rifamycin derivatives were tested for their effect on this enzyme 100 • 101 . Whereas the majority ofsemi-synthetic rifamycins are inactive, or moderately active, some derivatives are quite effective inhibitors, blocking the RNA-dependent DNA polymerase reaction at concentrations ofless than 20 J..Lg ml-1 . Most ofthese compounds have bulky substituents in position 3, e.g. the hydrazones and oximes of3-formyl rifamycin SV. Also the 3-cyclic amino derivatives of rifamycin SV that contain cyclohexyl substituents, exhibitahigh degree ofactivity on DNA polymerase of MSV 102 . This extensive screening has demonstrated the possibility of reaching a relatively high activity against reverse transcriptase through adequate modification ofthe rifamycin molecule. But a question immediately arises concerning the selectivity of action of these derivatives. In a screening of certain rifamycin derivatives for their effect on animal polymerases it was found that some ofthem completely inhibit the calfthymus DNA-dependent RNA polymerase AI and B activities at concentrations of20 to 40 J..Lg ml- 1 103 . Among the most active are the same derivatives, such as rifamycin AF I ABDP and rifamycin AF /013 (octyloxime of 3-formyl rifamycin SV), selected for their high activity on reverse transcriptase. The Iack of specificity of some of these derivatives is indicated by some selected biological data reported in Table 7 103 • 104 . The two derivatives AF/ABDP cis and AF/013, active on RL V reverse transcriptase, show a remarkable loss of activity against sensitive S. aureus strain in the presence of bovine serum albumin, good activity against a S. aureus strain resistant to rifarnpicin, high inhibitory effect on animal DNA-dependent RNA polymerases and a remarkably acute toxicity in mice. Therefore it seems that thesederivatives cannot be used as specific inhibitors of RNA-dependent DNA polymerase.
On the contrary rifampicin, which is inactive on reverse transcriptase and selectively active on bacterial RNA polymerase, shows only a minor loss of antibacterial activity in the presence of bovine serum alburnen, no activity against animal RNA polymerases and is less toxic than the other compounds.
Allthese data tend to indicate that for some rifamycin derivatives a higher activity against reverse transcriptase was achieved tagether with a broader spectrum of activity against other transcriptases and therefore with poor selectivity. This could not be the case for other derivatives and in fact Gallo et a/. 104 pointed out that N -demethylrifampicin and 3-(2,4-dinitrophenylhydrazonomethyl) rifamycin SV inhibit leukaemic polymerases more strongly than the analogaus normal enzymes ( Table 8) . Furthermore some rifamycin derivatives, active on reverse transcriptases of both human and viral origin, have been found to be more toxic for fresh human leukaemic blood cells than for normal proliferating blood cells 105 . Although the mechanism ofthe selective toxicity for the leukaemic blood cells is not clarified, and is not necessarily related to the inhibitory activity on reverse transcriptase, this effect could be chosen for the selection of potentially useful chemotherapeutic agents.
In summary, the screening of many semisynthetic rifamycins for their activity on reverse transcriptase revealed a series of potent, but not specific, inhibitors of this polymerase. Only a few derivatives seem to have a moderate specificity ofaction against this enzyme. On the other hand, viral and cellular polymerases have remarkable structural differences as indicated by their 407 P. SENSI Table 8 . Relative differences between inhibition of purified DNA polymerase activities from leukaemic and normal (1788) lymphoblasts 104 
Rifamycin
,. different template specificities and cellular functions 102 . Therefore, at least theoretically, it should be possible to develop specific inhibitors of the DNA polymerase of RNA tumour viruses.
A systematic study of semisynthetic or new natural ansamycins with new modifications both in the aromatic nucleus and on the ansa chain could perhaps lead to a knowledge of the structural requirements for the specific inhibitory effect on reverse transcriptase. A product with such a property will be a powerful tool for understanding the role of the reverse transcriptase in the process of tumour induction and propagation. Furthermore, if the enzyme plays adefinite role in these processes, a specific inhibitorwill have the necessary requisite of a potential chemotherapeutic agent.
